» Articles » PMID: 35662922

Inhibitory Effects of Macelignan on Tau Phosphorylation and Aβ Aggregation in the Cell Model of Alzheimer's Disease

Overview
Journal Front Nutr
Date 2022 Jun 6
PMID 35662922
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder mainly affecting old population. In this study, two Tau overexpressing cell lines (SH-SY5Y/Tau and HEK293/Tau), N2a/SweAPP cell line, and 3× Transgene (APPswe/PS1M146V/TauP301L) mouse primary nerve cell lines were used as AD models to study the activity and molecular mechanism of macelignan, a natural compound extracted from , against AD. Our study showed that macelignan could reduce the phosphorylation of Tau at Thr 231 site, Ser 396 site, and Ser 404 site in two overexpressing Tau cell lines. It also could decrease the phosphorylation of Tau at Ser 404 site in mouse primary neural cells. Further investigation of its mechanism found that macelignan could reduce the phosphorylation of Tau by increasing the level of autophagy and enhancing PP2A activity in Tau overexpressing cells. Additionally, macelignan could activate the PERK/eIF2α signaling pathway to reduce BACE1 translation, which further inhibits the cleavage of APP and ultimately suppresses Aβ deposition in N2a/SweAPP cells. Taken together, our results indicate that macelignan has the potential to be developed as a treatment for AD.

Citing Articles

Targeting Protein Aggregates with Natural Products: An Optional Strategy for Neurodegenerative Diseases.

Xiang L, Wang Y, Liu S, Liu B, Jin X, Cao X Int J Mol Sci. 2023; 24(14).

PMID: 37511037 PMC: 10379780. DOI: 10.3390/ijms241411275.

References
1.
Fan L, Chiu M . Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer's disease. Neuropsychiatr Dis Treat. 2014; 10:439-51. PMC: 3956689. DOI: 10.2147/NDT.S45143. View

2.
Martin L, Latypova X, Terro F . Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem Int. 2011; 58(4):458-71. DOI: 10.1016/j.neuint.2010.12.023. View

3.
Lane C, Hardy J, Schott J . Alzheimer's disease. Eur J Neurol. 2017; 25(1):59-70. DOI: 10.1111/ene.13439. View

4.
Gauthier S, Feldman H, Schneider L, Wilcock G, Frisoni G, Hardlund J . Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016; 388(10062):2873-2884. PMC: 5164296. DOI: 10.1016/S0140-6736(16)31275-2. View

5.
Bernard A, Klionsky D . Defining the membrane precursor supporting the nucleation of the phagophore. Autophagy. 2013; 10(1):1-2. PMC: 4389864. DOI: 10.4161/auto.27242. View